Intel Staves Off the Dow's Drop

Smith & Nephew's stock recedes from recent highs as investors continue to circle the possibility of a takeover for this medical-device maker

Jun 24, 2014 at 2:30PM
Daily Fool

After sailing in the green for much of the day and flirting with a new record high, the Dow Jones Industrial Average (DJINDICES:^DJI), has plunged 83 points into the red as of 2:35 p.m. EDT. Investors shrugged off stronger than expected housing sales figures, leaving all but a handful of blue-chip stocks down on the day, Intel (NASDAQ:INTC) has gained 1.3% to become the strongest Dow stock of the day. Meanwhile, medical-device giant Smith & Nephew (NYSE:SNN) today has seen shares back away from its recent run-up. Let's catch up on what you need to know.

Is Intel's gain worth it?
Intel's released little news today to account for its rise, but investors are rallying around the chipmaker stock that already has jumped by more than 17% year to date. The semiconductor's upgraded guidance earlier in June certainly has helped shares as of late, but given the improved projections' reliance on finite upgrades of PCs in the move away from the Windows XP operating system, investors need to keep their eyes on the long-term with this chipmaker.

Intel's PC Group continues to struggle, and the future for this niche in the long run doesn't look bright. While Intel's Data Center Group has performed admirably in its stead as a growth driver -- racking up more than 10% year-over-year revenue growth in the company's most recent quarter -- the PC division makes up nearly two-thirds of Intel's overall revenue. Finding new markets to tap into is Intel's best hope to spark a long-term trend higher, but as fellow Fool Ashraf Eassa notes, the company is still lagging behind the leaders in the chip market. Intel's gains this year have been promising, and the company is still valued cheaper than rivals such as Qualcomm and AMD on a price-to-earnings basis, but Intel has plenty of work to do to shore up its future. Long-term investors should stay cautious with this pick's run-up in 2014.

Around the market today, the health-care sector has been home to one of the day's biggest losers among large-cap stocks so far. Medical-device leader and takeover speculation target Smith & Nephew (NYSE:SNN) has dropped by more than 2.5% as investors back down from the stock's recent spike. Over the past year, Smith & Nephew's stock has shot up more than 50% -- far past top rivals in the orthopedics sector.

SNN Chart

SNN data by YCharts.

Today's drop doesn't mean that Smith & Nephew is falling off of the merger and acquisition bandwagon, though: While orthopedics giant Stryker (NYSE:SYK) will have to wait some time before approaching Smith & Nephew about a potential deal, don't expect the company to sit quietly while rival device makers such as Medtronic and Zimmer Holdings have beefed up through market-shaking acquisitions.

Stryker has maintained respectable organic growth lately, with nearly 6% sales growth year over year in its reconstructive division last quarter and 7% neurotech and spine sales growth. The company's recent acquisitions, while smaller than Medtronic's blockbuster buy of Covidien or Zimmer's acquisition of Biomet, have been focused on the future, with MAKO Surgical adding the innovative edge of robotics to Stryker's portfolio. However, Zimmer's purchase particularly has Stryker trailing in the race to industry consolidation. Making a deal with Smith & Nephew would beef up Stryker's revenue and cement its place among the top orthopedics leaders while also giving it increased exposure to foreign markets.

This health care blockbuster could transform your financial future
Smith & Nephew may be on the downswing today, but savvy health care stock pickers know one secret to success in this sector: The best investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Covidien and Intel. The Motley Fool owns shares of Intel, Medtronic, Qualcomm, and Zimmer Holdings. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers